Cim LLC increased its stake in shares of Johnson & Johnson (NYSE:JNJ – Get Rating) by 6.0% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 9,807 shares of the company’s stock after buying an additional 556 shares during the quarter. Cim LLC’s holdings in Johnson & Johnson were worth $1,697,000 at the end of the most recent reporting period.
Several other institutional investors have also bought and sold shares of the stock. Morton Brown Family Wealth LLC increased its holdings in shares of Johnson & Johnson by 78.0% during the second quarter. Morton Brown Family Wealth LLC now owns 178 shares of the company’s stock worth $32,000 after buying an additional 78 shares in the last quarter. Goodman Advisory Group LLC acquired a new stake in Johnson & Johnson during the 2nd quarter valued at $39,000. First Bank & Trust boosted its stake in Johnson & Johnson by 69.6% in the second quarter. First Bank & Trust now owns 380 shares of the company’s stock worth $67,000 after purchasing an additional 156 shares in the last quarter. Heritage Wealth Management LLC bought a new stake in shares of Johnson & Johnson during the second quarter worth $84,000. Finally, Timber Creek Capital Management LLC raised its holdings in shares of Johnson & Johnson by 225.0% in the third quarter. Timber Creek Capital Management LLC now owns 650 shares of the company’s stock valued at $106,000 after buying an additional 450 shares during the last quarter. Institutional investors and hedge funds own 67.94% of the company’s stock.
Analysts Set New Price Targets
Several equities research analysts have weighed in on the stock. Bank of America lowered their price objective on shares of Johnson & Johnson from $185.00 to $178.00 and set a “neutral” rating for the company in a research report on Friday, October 14th. Raymond James lowered their price target on shares of Johnson & Johnson from $192.00 to $185.00 and set an “outperform” rating for the company in a report on Wednesday, October 19th. Citigroup upped their price objective on Johnson & Johnson from $198.00 to $205.00 and gave the stock a “buy” rating in a report on Monday, December 12th. Credit Suisse Group started coverage on Johnson & Johnson in a research note on Thursday, November 17th. They issued a “neutral” rating and a $170.00 target price for the company. Finally, Sanford C. Bernstein cut their price target on Johnson & Johnson from $194.00 to $190.00 in a research note on Wednesday, October 19th. Seven equities research analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $181.75.
Johnson & Johnson Stock Performance
Johnson & Johnson (NYSE:JNJ – Get Rating) last announced its quarterly earnings results on Tuesday, January 24th. The company reported $2.35 earnings per share for the quarter, topping analysts’ consensus estimates of $2.23 by $0.12. Johnson & Johnson had a net margin of 19.95% and a return on equity of 35.37%. The company had revenue of $23.71 billion for the quarter, compared to analysts’ expectations of $23.90 billion. During the same period last year, the firm posted $2.13 earnings per share. The business’s quarterly revenue was down 4.4% compared to the same quarter last year. As a group, sell-side analysts forecast that Johnson & Johnson will post 10.04 earnings per share for the current year.
Johnson & Johnson Announces Dividend
The firm also recently declared a quarterly dividend, which will be paid on Tuesday, March 7th. Shareholders of record on Tuesday, February 21st will be issued a $1.13 dividend. The ex-dividend date is Friday, February 17th. This represents a $4.52 annualized dividend and a dividend yield of 2.69%. Johnson & Johnson’s dividend payout ratio (DPR) is currently 62.95%.
In related news, VP Thibaut Mongon sold 35,246 shares of the stock in a transaction that occurred on Friday, November 4th. The stock was sold at an average price of $171.18, for a total transaction of $6,033,410.28. Following the completion of the sale, the vice president now directly owns 40,133 shares of the company’s stock, valued at approximately $6,869,966.94. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. In other Johnson & Johnson news, CFO Joseph J. Wolk sold 14,781 shares of the stock in a transaction dated Tuesday, December 13th. The stock was sold at an average price of $179.60, for a total transaction of $2,654,667.60. Following the completion of the transaction, the chief financial officer now owns 35,812 shares in the company, valued at approximately $6,431,835.20. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, VP Thibaut Mongon sold 35,246 shares of the business’s stock in a transaction dated Friday, November 4th. The shares were sold at an average price of $171.18, for a total value of $6,033,410.28. Following the completion of the sale, the vice president now owns 40,133 shares in the company, valued at $6,869,966.94. The disclosure for this sale can be found here. Insiders have sold 233,611 shares of company stock worth $40,960,735 in the last 90 days. Corporate insiders own 0.35% of the company’s stock.
About Johnson & Johnson
Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women’s health, and wound care markets.
- Get a free copy of the StockNews.com research report on Johnson & Johnson (JNJ)
- Pliant Therapeutics Gaps 34% Higher: More Upside To Come?
- How Will Early 2023 Layoffs Affect These 5 Biotech Stocks?
- Is the Pain Over for Baudax Bio Investors after a 70% Spike?
- Will Rocket Lab’s First U.S. Launch Send Stock Into Stratosphere?
- Is It Time To Get Aggressive With Defense Stocks?
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.